<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">The present trial aims to investigate the treatment response to 'conventional whole brain radiotherapy' and 'stereotactic radiotherapy' (SRS) in SCLC patients. The primarily investigated endpoint is neurocognitive function, as objectively measured by significant deterioration in Hopkins Verbal Learning Test – Revised (HVLT-R) total recall at 3 months [
 <xref ref-type="bibr" rid="CR20">20</xref>]. Secondary endpoints include intracranial progression (local tumor progression, number of new cerebral metastases), extracranial progression, overall survival, death due to brain metastases, local (neurological) progression-free survival, progression-free survival, changes in other cognitive performance measures, quality of life, and toxicity.
</p>
